KR20230027213A - 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 - Google Patents

세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 Download PDF

Info

Publication number
KR20230027213A
KR20230027213A KR1020237002102A KR20237002102A KR20230027213A KR 20230027213 A KR20230027213 A KR 20230027213A KR 1020237002102 A KR1020237002102 A KR 1020237002102A KR 20237002102 A KR20237002102 A KR 20237002102A KR 20230027213 A KR20230027213 A KR 20230027213A
Authority
KR
South Korea
Prior art keywords
mmol
trans
cyclohexyl
alkyl
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237002102A
Other languages
English (en)
Korean (ko)
Inventor
매튜 디. 알렉산더
매튜 디. 코레아
디팍 달비
버지니아 헤더 샤론 그랜트
조슈아 한센
3세 로이 엘. 해리스
에반 제이. 호른
데후아 후앙
크리스토퍼 메인
스티븐 노리스
베로니크 플란테빈-크레니트스키
존 제이. 사피엔자
리다 테흐라니
브랜든 더블유. 화이트필드
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20230027213A publication Critical patent/KR20230027213A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020237002102A 2020-06-24 2021-06-23 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 Pending KR20230027213A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043612P 2020-06-24 2020-06-24
US63/043,612 2020-06-24
PCT/US2021/038625 WO2021262812A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (1)

Publication Number Publication Date
KR20230027213A true KR20230027213A (ko) 2023-02-27

Family

ID=79032406

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237002102A Pending KR20230027213A (ko) 2020-06-24 2021-06-23 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Country Status (9)

Country Link
US (2) US11739075B2 (https=)
EP (1) EP4171568B1 (https=)
JP (1) JP7778095B2 (https=)
KR (1) KR20230027213A (https=)
CN (1) CN115955979B (https=)
AR (1) AR122725A1 (https=)
ES (1) ES3048462T3 (https=)
TW (1) TW202216681A (https=)
WO (1) WO2021262812A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
WO2022262782A1 (zh) * 2021-06-17 2022-12-22 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
JP2024534223A (ja) 2021-09-01 2024-09-18 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Bcl-2ファミリータンパク質を分解する化合物及びその医薬的な応用
AU2023278399A1 (en) 2022-06-02 2024-12-19 Xizang Haisco Pharmaceutical Co., Ltd. Compound for inhibiting or degrading bcl6 and use thereof in pharmaceutics
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 3-苯基丙基胺衍生物
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2015179438A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. ターゲティングされたアンドロゲン受容体分解のための化合物および方法
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110317192A (zh) * 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物及使用它们的治疗方法
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Also Published As

Publication number Publication date
CN115955979A (zh) 2023-04-11
EP4171568B1 (en) 2025-08-27
US11739075B2 (en) 2023-08-29
WO2021262812A1 (en) 2021-12-30
JP7778095B2 (ja) 2025-12-01
EP4171568A4 (en) 2024-07-24
EP4171568A1 (en) 2023-05-03
TW202216681A (zh) 2022-05-01
US12227490B2 (en) 2025-02-18
ES3048462T3 (en) 2025-12-10
CN115955979B (zh) 2025-12-05
US20210403453A1 (en) 2021-12-30
JP2023531709A (ja) 2023-07-25
AR122725A1 (es) 2022-09-28
US20230348431A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
EP4171568B1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
US12103920B2 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
US11560371B2 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
WO2022272074A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
US20250100995A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
KR20240025613A (ko) 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240621

Comment text: Request for Examination of Application